Ramipex 0.25/Ramipex 1 Use In Pregnancy & Lactation

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Pramipexole should be used during pregnancy only if the potential benefit justifies the potential risk the fetus.
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from pramipexole, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
The effect on pregnancy and lactation has not been investigated in humans. Pramipexole was not teratogenic in rats and rabbits, but was embryotoxic in the rat at maternotoxic doses. Pramipexole (Ramipex) should not be used during pregnancy unless clearly necessary, i.e. if the potential benefit justifies the potential risk to the fetus.
As pramipexole treatment inhibits secretion of prolactin in humans, inhibition of lactation is expected. The excretion of pramipexole into breast milk has not been studied in women. In rats, the concentration of active substance-related radioactivity was higher in breast milk than in plasma.
In the absence of human data, Pramipexole (Ramipex) should not be used during breastfeeding. However, if its use is unavoidable, breast-feeding should be discontinued.